

Title (en)

SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS

Title (de)

AUSGEWÄHLTE CGRP-ANTAGONISTEN, VERFAHREN ZU DEREN HERSTELLUNG SOWIE DEREN VERWENDUNG ALS ARZNEIMITTEL

Title (fr)

ANTAGONISTES CGRP SELECTIONNES, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION COMME MEDICAMENT

Publication

EP 1917256 A2 20080507 (DE)

Application

EP 06778243 A 20060815

Priority

- EP 2006065314 W 20060815
- DE 102005038831 A 20050817
- DE 102005050953 A 20051025

Abstract (en)

[origin: WO2007020261A2] The invention relates to the CGRP antagonists of general formula (I) in which R1, R2, R3 and R4 are defined as in claim 1, to their tautomers, isomers, diastereoisomers and enantiomers, hydrates, mixtures and their salts as well as the hydrates of the salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, as well as to the compounds of general formula (I) in which one or more hydrogen atoms are exchanged for deuterium, to medicaments containing these compounds, the use thereof and to methods for the production thereof.

IPC 8 full level

C07D 401/14 (2006.01); **A61K 31/4545** (2006.01); **A61P 25/06** (2006.01)

CPC (source: EP KR US)

A61K 31/4545 (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 1/02** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 1/12** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/30** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/16** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/36** (2017.12 - EP); **A61P 27/16** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 401/14** (2013.01 - EP KR US); **C07D 405/14** (2013.01 - EP US)

Citation (search report)

See references of WO 2007020261A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

WO 2007020261 A2 20070222; **WO 2007020261 A3 20080821**; AR 056460 A1 20071010; AU 2006281416 A1 20070222; BR PI0614831 A2 20090519; CA 2618834 A1 20070222; DE 102005038831 A1 20070222; DE 102005050953 A1 20070426; EA 200800439 A1 20080829; EC SP088194 A 20080326; EP 1917256 A2 20080507; IL 189497 A0 20080807; JP 2009505985 A 20090212; JP 2011256200 A 20111222; JP 4852607 B2 20120111; KR 20080039990 A 20080507; MX 2008001977 A 20080325; NO 20076680 L 20080430; PE 20070355 A1 20070430; PE 20100570 A1 20100816; TW 200740795 A 20071101; US 2007049581 A1 20070301; US 2010004228 A1 20100107; US 2011034444 A1 20110210; US 7579341 B2 20090825; US 7858622 B2 20101228; UY 29749 A1 20070330

DOCDB simple family (application)

EP 2006065314 W 20060815; AR P060103563 A 20060816; AU 2006281416 A 20060815; BR PI0614831 A 20060815; CA 2618834 A 20060815; DE 102005038831 A 20050817; DE 102005050953 A 20051025; EA 200800439 A 20060815; EC SP088194 A 20080215; EP 06778243 A 20060815; IL 18949708 A 20080213; JP 2008526494 A 20060815; JP 2011189050 A 20110831; KR 20087006215 A 20080313; MX 2008001977 A 20060815; NO 20076680 A 20071228; PE 2006000989 A 20060815; PE 2010000353 A 20060815; TW 95130108 A 20060816; US 46251106 A 20060804; US 48602609 A 20090617; US 90777110 A 20101019; UY 29749 A 20060814